Complete androgen insensitivity syndrome

Last updated
Complete androgen insensitivity syndrome
Other namesComplete androgen resistance syndrome
Androgen receptor 3-d model.jpg
AIS results when the function of the androgen receptor (AR) is impaired. The AR protein (pictured) mediates the effects of androgens in the human body.
Specialty Gynaecology, endocrinology   OOjs UI icon edit-ltr-progressive.svg

Complete androgen insensitivity syndrome (CAIS) is an AIS condition that results in the complete inability of the cell to respond to androgens. [1] [2] [3] As such, the insensitivity to androgens is only clinically significant when it occurs in individuals who are exposed to significant amounts of testosterone at some point in their lives. [1] The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does allow, without significant impairment, female genital and sexual development [3] [4] in those with the condition.

Contents

All human fetuses begin fetal development looking similar, with both the Müllerian duct system (female) and the Wolffian duct system (male) developing. Sex differentiation begins with the gonads, which in XX individuals become ovaries, and in XY individuals (including those with CAIS) typically become testicles due to the presence of the Y chromosome. It is at the seventh week of gestation that the bodies of non-CAIS individuals with the XY karyotype begin their masculinization: i.e., the Wolffian duct system is promoted and the Müllerian duct system is suppressed (the reverse happens with typically developing females). This process is triggered by androgens produced by the testicles. The bodies of unaffected XY individuals masculinize by, among other things, enlarging the genital tubercle into a penis, which in females becomes the clitoris, while what in females becomes the labia fuses to become the scrotum of males (where the testicles will later descend). [ citation needed ]

XY individuals affected by CAIS develop a normal external female habitus, despite the presence of a Y chromosome, [1] [5] [6] [7] [8] [9] but internally, they will lack a uterus, and the vaginal cavity will be shallow, while the gonads, which differentiated into testes in the earlier separate process also triggered by their Y chromosome, will remain undescended in the place. This results not only in infertility in individuals with CAIS, but also presents a risk of gonadal cancer later on in life. [10]

CAIS is one of the three categories of androgen insensitivity syndrome (AIS) since AIS is differentiated according to the degree of genital masculinization: complete androgen insensitivity syndrome (CAIS) when the external genitalia is that of a typical female, mild androgen insensitivity syndrome (MAIS) when the external genitalia is that of a typical male, and partial androgen insensitivity syndrome (PAIS) when the external genitalia is partially, but not fully masculinized. [1] [2] [5] [6] [7] [11] [12] [13] [14]

Androgen insensitivity syndrome is the largest single entity that leads to 46, XY undermasculinization. [15]

Signs and symptoms

Physical

Persons with a complete androgen insensitivity have a typical female external phenotype, despite having a 46,XY karyotype. Complete androgen insensitivity syndrome.jpg
Persons with a complete androgen insensitivity have a typical female external phenotype, despite having a 46,XY karyotype.

Individuals with complete androgen insensitivity syndrome (grades 6 and 7 on the Quigley scale) are born with an external female phenotype, without any signs of genital masculinization, despite having a 46,XY karyotype. [18] CAIS is usually recognized at puberty, [2] which may be slightly delayed, [19] but is otherwise normal except for absent menses and diminished or absent secondary terminal hair. [1] Axillary hair (i.e. armpit hair) fails to develop in one third of all cases. [20] The vulva is normal, although the labia and clitoris are sometimes underdeveloped. [21] [22] Vaginal depth varies widely for CAIS, but is typically shorter than normal; [1] one study of eight people with CAIS measured the average vaginal depth to be 5.9 cm [23] (vs. 11.1 ± 1.0 cm for unaffected women [24] ). In some extreme cases, the vagina has been reported to be aplastic (resembling a "dimple"), though the exact incidence of this is unknown. [25]

The gonads in people with CAIS are testes; during the embryonic stage of development, testes form in an androgen-independent process that occurs due to the influence of the SRY gene on the Y chromosome. [26] [27] They may be located intra-abdominally, at the internal inguinal ring, or may herniate into the labia majora, often leading to the discovery of the condition. [1] [28] [29] [30] Testes in those affected have been found to be atrophic upon gonadectomy. [31]

Testosterone produced by the testes cannot be directly used due to the mutant androgen receptor that characterizes CAIS; instead, it is aromatized into estrogen, which effectively feminizes the body and accounts for the normal female phenotype observed in CAIS. [1] However, up to 5% of individuals with CAIS do not have an AR mutation. [2] The receptor in question is encoded by the AR gene located on the X chromosome at Xq11–12. At least 15 different mutations were known in 2003, and they are all recessive, which makes the disease follow X-linked recessive inheritance. [20]

Immature sperm cells in the testes do not mature past an early stage, as sensitivity to androgens is required in order for spermatogenesis to complete. [32] [33] Germ cell malignancy risk, once thought to be relatively high, is now thought to be approximately 2%. [34] Wolffian structures (the epididymides, vasa deferentia, and seminal vesicles) are typically absent, but will develop at least partially in approximately 30% of cases, depending on which mutation is causing the CAIS. [35] The prostate, like the external male genitalia, cannot masculinize in the absence of androgen receptor function, and thus remains in the female form. [18] [36] [37] [38]

The Müllerian system typically regresses the same way it does in unaffected male fetuses due to anti-Müllerian hormone originating from the Sertoli cells of the testes. [19] Thus, people with CAIS, despite having a vagina due to androgen insensitivity, are born without fallopian tubes, a cervix, or a uterus, [19] and the vagina ends "blindly" in a pouch. [1] Müllerian regression does not fully complete in some cases of CAIS, resulting in Müllerian "remnants". [19] Although rare, a few cases of people diagnosed with CAIS and having Müllerian structures have been reported. In one exceptional case, a 22-year-old with CAIS was found to have a cervix, uterus, and fallopian tubes. [39] In an unrelated case, almost fully developed uterus was found in a 22-year-old adult with CAIS. [38]

Other subtle differences that have been reported include slightly longer limbs and larger hands and feet due to a proportionally greater stature than unaffected women, [40] [41] [42] larger teeth, [43] [44] minimal or no acne, [45] well developed breasts, [46] a greater incidence of meibomian gland dysfunction (i.e. dry eye syndromes and light sensitivity), [47] and dry skin and hair resulting from a lack of sebum production. [48]

Endocrine

Hormone levels have been reported in gonadally intact people with CAIS in a number of studies. [49] [50] Hormone levels are similar to those of males, including high testosterone levels and relatively low estradiol levels. [49] [50] However, luteinizing hormone (LH) levels are elevated while sex hormone-binding globulin (SHBG) levels are more consistent with those of females. [49] [50] [51] People with CAIS have low levels of progesterone similarly to males. [52] [53] [54] The production rates of testosterone, estradiol, and estrone have been reported to be higher in gonadally intact with CAIS than in men. [55] [56]

Hormone levels in gonadally intact adolescent and adult females with complete androgen insensitivity syndrome
StudyLocationnAge
(years)		LH
(IU/L)		FSH
(IU/L)		T
(ng/dL)		DHT
(ng/dL)		E2
(pg/mL)		P4
(ng/mL)		SHBG
(nmol/L)
Schindler (1975)Tübingen, DE4 ? (17–22) ?a ?a1040 ± 30079 ± 3036.7 ± 7.10.06 ± 0.02 ?
Blumenthal (1982)Johannesburg, ZA419 (18–28)70 (8–97)14 (6–22)1356 (1240–1577) ?40 (26–79)0.96 (0.68–1.76) ?
Melo (2003)Sao Paulo, BR816.5 (14–34)26 (14–43)7.4 (3.5–16)346 (173–1040) ?30 (22–40) ? ?
Audi (2010)Barcelona, ES1120 (13.5–40)10 (<0.1–35)2.3 (0.4–23.4)576 (144–1350) ?33 (20–73) ?52 (22–128)
Doehnert (2015)Lübeck, DE/Pisa, IT4217.3 (14–50)18.5 (5.5–51.1)3.5 (0.4–16.3)576 (173–1450) ?31 (5–70) ?53 (15–99)
King (2017)London, UK3119.7 (13.4–52.3)24.2 (13–59.1)4.6 (1.1–68.9)640 (233–1260) ?35 (12–63) ? ?
Male ref. range––Adult1–101–7346 (202–1010) ?30 (10–50)<0.610–50
Female ref. range––Adult2–6.62–6.643 (20–86) ?80 (10–395)<3.2–2530–90
Abbreviations: LH = Luteinizing hormone. FSH = Follicle-stimulating hormone. T = Testosterone. DHT = Dihydrotestosterone. E2 = Estradiol. P4 = Progesterone. SHBG = Sex hormone-binding globulin. Notes: Values are mean (range) or mean ± standard deviation. Footnotes:a = LH = 73.2 ± 9.2 ng LER 907/mL, FSH = 40.2 ± 20.0 ng LER 907/mL. Sources: See template.

Comorbidity

Histopathology of testicular tissue showing immature germ cells and spermatagonia with decreased tubular diameter. Scattered groups of Leydig cells appearing immature. Histopathology of androgen insensitivity.jpg
Histopathology of testicular tissue showing immature germ cells and spermatagonia with decreased tubular diameter. Scattered groups of Leydig cells appearing immature.

All forms of androgen insensitivity, including CAIS, are associated with infertility, though exceptions have been reported for both the mild and partial forms. [4] [5] [7] [57] [58] [59]

CAIS is associated with a decreased bone mineral density. [60] [61] [62] [63] [64] [65] Some have hypothesized that the decreased bone mineral density observed in women with CAIS is related to the timing of gonadectomy and inadequate estrogen supplementation. [64] However, recent studies show that bone mineral density is similar whether gonadectomy occurs before or after puberty, and is decreased despite estrogen supplementation, leading some to hypothesize that the deficiency is directly attributable to the role of androgens in bone mineralization. [60] [61] [62] [63]

CAIS is also associated with an increased risk for gonadal tumors (e.g. germ cell malignancy) in adulthood if gonadectomy is not performed. [34] [66] [67] [68] The risk of malignant germ cell tumors in women with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. [68] The incidence of gonadal tumors in childhood is thought to be relatively low; a recent review of the medical literature [66] found that only three cases of malignant germ cell tumors in prepubescent girls have been reported in association with CAIS in the last 100 years. Some have estimated the incidence of germ cell malignancy to be as low as 0.8% before puberty. [1]

Vaginal hypoplasia, a relatively frequent finding in CAIS and some forms of PAIS, [23] [25] is associated with sexual difficulties including vaginal penetration difficulties and dyspareunia. [21] [25]

At least one study indicates that individuals with an DSD condition may be more prone to psychological difficulties, due at least in part to parental attitudes and behaviors, [69] and concludes that preventative long-term psychological counseling for parents as well as for affected individuals should be initiated at the time of diagnosis.

Lifespan is not thought to be affected by AIS. [1]

Despite the well-developed breasts in CAIS women, and for reasons that are not well-understood, breast cancer has never been reported in CAIS women and does not seem to occur or occurs only rarely. [70] [71] [72] [73] [74] [75] Only a case report of juvenile fibroadenoma exists. [70] [72] [76] A few cases of breast cancer have been reported in individuals with partial androgen insensitivity syndrome however. [73] [77] [78]

Diagnosis

Bilateral inguinal hernia. CAIS is not usually suspected until after puberty unless an inguinal hernia presents. Complete androgen insensitivity presenting with inguinal hernia.jpg
Bilateral inguinal hernia. CAIS is not usually suspected until after puberty unless an inguinal hernia presents.

CAIS is usually not suspected until the menses fail to develop at puberty, or an inguinal hernia presents during premenarche. [1] [2] As many as 1–2% of prepubertal girls that present with an inguinal hernia will also have CAIS. [1] [19]

A diagnosis of CAIS or Swyer syndrome can be made in utero by comparing a karyotype obtained by amniocentesis with the external genitalia of the fetus during a prenatal ultrasound. [2] [80] Many infants with CAIS do not experience the normal, spontaneous neonatal testosterone surge, a fact which can be diagnostically exploited by obtaining baseline luteinizing hormone and testosterone measurements, followed by a human chorionic gonadotropin (hCG) stimulation test. [1]

The main differentials for CAIS are complete gonadal dysgenesis (Swyer syndrome) and Müllerian agenesis (Mayer-Rokitansky-Kuster-Hauser syndrome or MRKH). [1] [25] Both CAIS and Swyer syndrome are associated with a 46,XY karyotype, whereas MRKH is not; MRKH can thus be ruled out by checking for the presence of a Y chromosome, which can be done either by fluorescence in situ hybridization (FISH) analysis or on full karyotype. [1] Swyer syndrome is distinguished by the presence of a uterus, poor breast development and shorter stature. [1] The diagnosis of CAIS is confirmed when androgen receptor (AR) gene sequencing reveals a mutation, although up to 5% of individuals with CAIS do not have an AR mutation. [2]

Up until the 1990s, a CAIS diagnosis was often hidden from the affected individual, the individual's family, or both. [18] It is current practice to disclose the genotype at the time of diagnosis, particularly when the affected individual is at least of adolescent age. [18] If the affected individual is a child or infant, it is generally up to the parents, often in conjunction with a psychologist, to decide when to disclose the diagnosis. [18]

Management

Management of AIS is currently limited to symptomatic management; methods to correct a malfunctioning androgen receptor protein that result from an AR gene mutation are not currently available. Areas of management include sex assignment, genitoplasty, gonadectomy in relation to tumor risk, hormone replacement therapy, and genetic and psychological counseling. Non-consensual interventions are still often performed, although general awareness on the resulting psychological traumatization is rising. [81]

Sex assignment and sexuality

Most individuals with CAIS are raised as females. [1] They are born with an external phenotype of a typical female and are thought to be usually heterosexual with a female gender identity; [41] [82] however, some research has suggested that individuals with CAIS are more likely to have more variable gender outcomes and a non-primarily heterosexual sexual orientation than relatively similar control groups of those with MRKH syndrome and PCOS, contradicting this belief. [83] At least two case studies have reported male gender identity in individuals with CAIS. [82] [84]

Vaginal length in 8 women with CAIS before and after dilation therapy as first line treatment. The normal reference range (shaded) is derived from 20 control women. Duration and extent of therapy varied; the median time to completion of treatment was 5.2 months, and the median number of 30-minute dilations per week was 5. Results of vaginal lengthening by pressure dilation methods.jpg
Vaginal length in 8 women with CAIS before and after dilation therapy as first line treatment. The normal reference range (shaded) is derived from 20 control women. Duration and extent of therapy varied; the median time to completion of treatment was 5.2 months, and the median number of 30-minute dilations per week was 5.

Dilation therapy

Most cases of vaginal hypoplasia associated with CAIS can be corrected using non-surgical pressure dilation methods. [23] [25] The elastic nature of vaginal tissue, as demonstrated by its ability to accommodate the differences in size between a tampon, a penis, and a baby's head, [85] make dilation possible even in cases when the vaginal depth is significantly compromised. [23] [25] Treatment compliance is thought to be critical to achieve satisfactory results. [21] [23] [25] Dilation can also be achieved via the Vecchietti procedure, which stretches vaginal tissues into a functional vagina using a traction device that is anchored to the abdominal wall, subperitoneal sutures, and a mold that is placed against the vaginal dimple. [25] Vaginal stretching occurs by increasing the tension on the sutures, which is performed daily. [25] The non-operative pressure dilation method is currently recommended as the first choice, since it is non-invasive, and highly successful. [25] Vaginal dilation should not be performed before puberty. [34]

Gonadectomy

While it was often recommended that women with CAIS eventually undergo gonadectomy to mitigate cancer risk, [1] there are differing opinions regarding the necessity and timing of gonadectomy. [86] The risk of malignant germ cell tumors with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. [68] However, only three cases of malignant germ cell tumors in prepubescent girls with CAIS have been reported in the last 100 years. [66] The youngest of these children was 14 years old. [87] Individuals with CAIS naturally go through puberty via the aromatization of testosterone into estrogens. Therefore, removal of the gonads will result in an individual requiring hormone replacement therapy. Gonadectomy is generally not recommended before puberty to allow for puberty to occur spontaneously. [88] [89] [90] Some individuals with CAIS may choose to go on testosterone HRT rather than estrogen. Research suggests that testosterone is at least as beneficial as estrogen replacement therapy and possibly improves outcomes in certain areas of well-being. [91]

If gonadectomy is performed early, then puberty must be artificially induced using gradually increasing doses of estrogen. [1] If gonadectomy is performed late, then puberty will occur on its own, due to the aromatization of testosterone into estrogen. [1] At least one organization, the Australasian Paediatric Endocrine Group, classifies the cancer risk associated with CAIS as low enough to recommend against gonadectomy, although it warns that the cancer risk is still elevated above the general population, and that ongoing cancer monitoring is essential. [86] Some choose to perform gonadectomy if and when inguinal hernia presents. [1] Estrogen replacement therapy is critical to minimize bone mineral density deficiencies later in life. [62] [64]

Some individuals with CAIS may choose to retain their gonads. If this is the case, annual imaging of the gonads via MRI or ultrasound is recommended in order to monitor for signs of malignancy. [92] Diagnostic laparoscopy and biopsy are also to be considered if imaging is ambiguous.

Hormone replacement therapy

Some have hypothesized that supraphysiological levels of estrogen may reduce the diminished bone mineral density associated with CAIS. [62] Data has been published that suggests affected women who were not compliant with estrogen replacement therapy, or who had a lapse in estrogen replacement, experienced a more significant loss of bone mineral density. [61] [62] Progestin replacement therapy is usually seldom initiated as well. [1] Androgen replacement has been reported to increase a sense of well-being in gonadectomized people with CAIS, although the mechanism by which this benefit is achieved is not well understood. [1]

Counseling

It is no longer common practice to hide a diagnosis of CAIS from the affected individual or her family. [18] Parents of children with CAIS need considerable support in planning and implementing disclosure for their child once the diagnosis has been established. [1] [18] For parents with young children, information disclosure is an ongoing, collaborative process requiring an individualized approach that evolves in concordance with the child's cognitive and psychological development. [1] In all cases, the assistance of a psychologist experienced in the subject is recommended. [1] [18]

Neovaginal construction

Vaginal expander ZSI 200 NS Inflatable vaginal expander.jpg
Vaginal expander ZSI 200 NS
ZSI 200 NS vaginal expander stretching the female vagina ZSI 200 NS Vaginal Expander in Vagina.jpg
ZSI 200 NS vaginal expander stretching the female vagina

Many surgical procedures have been developed to create a neovagina, but none of them are ideal. [25] Surgical intervention should only be considered after non-surgical pressure dilation methods have failed to produce a satisfactory result. [25] Neovaginoplasty can be performed using skin grafts, a segment of bowel, ileum, peritoneum, an absorbable adhesion barrier (Intercede, made by Johnson & Johnson), [93] [94] buccal mucosa, amnion, dura mater. [25] [95] [96] or with the support of vaginal stents/expanders. [97] [98] Success of such methods should be determined by sexual function, and not just by vaginal length, as has been done in the past. [96] Ileal or cecal segments may be problematic because of a shorter mesentery, which may produce tension on the neovagina, leading to stenosis. [96] The sigmoid neovagina is thought to be self-lubricating, without the excess mucus production associated with segments of small bowel. [96] Vaginoplasty may create scarring at the introitus (the vaginal opening), which requires additional surgery to correct. Vaginal dilators are required postoperatively to prevent vaginal stenosis from scarring. [23] [25] Inflatable vaginal stents are placed in the vagina deflated and then gently inflated. [99] Other complications include bladder and bowel injuries. [25] Yearly exams are required as neovaginoplasty carries a risk of carcinoma, [25] although carcinoma of the neovagina is uncommon. [95] [96] Neither neovaginoplasty nor vaginal dilation should be performed before puberty. [25] [34]

Prognosis

Challenges presented to people affected by this condition include: psychologically coming to terms with the condition, difficulties with sexual function, infertility. Long-term studies indicate that with appropriate medical and psychological treatment, those with CAIS can be satisfied with their sexual function and psychosexual development. [41] Individuals with condition can lead active lives and expect a normal lifespan.

Epidemiology

It is estimated that CAIS occurs in 1 in 20,400 to 1 in 99,000 individuals with a 46,XY karyotype. [100] [101]

Nomenclature

Historically, CAIS has been referred to in the literature under a number of other names, including testicular feminization [syndrome] (deprecated) and Morris syndrome. [102] [103] PAIS has also been referred to as Reifenstein syndrome, which should not be confused with CAIS. [102] [103]

History

The first definitive description of CAIS was reported in 1817. [104] [105] The condition became more widely known after it was reviewed and named testicular feminization by American gynecologist John McLean Morris in 1953. [105]

People with CAIS

See also

Related Research Articles

<span class="mw-page-title-main">Androgen insensitivity syndrome</span> Medical condition

Androgen insensitivity syndrome (AIS) is a condition involving the inability to respond to androgens, typically due to androgen receptor dysfunction.

<span class="mw-page-title-main">Androgen</span> Any steroid hormone that promotes male characteristics

An androgen is any natural or synthetic steroid hormone that regulates the development and maintenance of male characteristics in vertebrates by binding to androgen receptors. This includes the embryological development of the primary male sex organs, and the development of male secondary sex characteristics at puberty. Androgens are synthesized in the testes, the ovaries, and the adrenal glands.

<span class="mw-page-title-main">XY gonadal dysgenesis</span> Medical condition

XY complete gonadal dysgenesis, also known as Swyer syndrome, is a type of defect hypogonadism in a person whose karyotype is 46,XY. Though they typically have normal vulvas, the person has underdeveloped gonads, fibrous tissue termed "streak gonads", and if left untreated, will not experience puberty. The cause is a lack or inactivation of an SRY gene which is responsible for sexual differentiation. Pregnancy is sometimes possible in Swyer syndrome with assisted reproductive technology. The phenotype is usually similar to Turner syndrome (45,X0) due to a lack of X inactivation. The typical medical treatment is hormone replacement therapy. The syndrome was named after Gerald Swyer, an endocrinologist based in London.

<span class="mw-page-title-main">Lipoid congenital adrenal hyperplasia</span> Medical condition

Lipoid congenital adrenal hyperplasia is an endocrine disorder that is an uncommon and potentially lethal form of congenital adrenal hyperplasia (CAH). It arises from defects in the earliest stages of steroid hormone synthesis: the transport of cholesterol into the mitochondria and the conversion of cholesterol to pregnenolone—the first step in the synthesis of all steroid hormones. Lipoid CAH causes mineralocorticoid deficiency in affected infants and children. Male infants are severely undervirilized causing their external genitalia to look feminine. The adrenals are large and filled with lipid globules derived from cholesterol.

Isolated hypogonadotropic hypogonadism (IHH), also called idiopathic or congenital hypogonadotropic hypogonadism (CHH), as well as isolated or congenital gonadotropin-releasing hormone deficiency (IGD), is a condition which results in a small subset of cases of hypogonadotropic hypogonadism (HH) due to deficiency in or insensitivity to gonadotropin-releasing hormone (GnRH) where the function and anatomy of the anterior pituitary is otherwise normal and secondary causes of HH are not present.

Hypoestrogenism, or estrogen deficiency, refers to a lower than normal level of estrogen. It is an umbrella term used to describe estrogen deficiency in various conditions. Estrogen deficiency is also associated with an increased risk of cardiovascular disease, and has been linked to diseases like urinary tract infections and osteoporosis.

<span class="mw-page-title-main">Familial male-limited precocious puberty</span> Medical condition

Familial male-limited precocious puberty, often abbreviated as FMPP, also known as familial sexual precocity or gonadotropin-independent testotoxicosis, is a form of gonadotropin-independent precocious puberty in which boys experience early onset and progression of puberty. Signs of puberty can develop as early as an age of 1 year.

Gonadal dysgenesis is classified as any congenital developmental disorder of the reproductive system characterized by a progressive loss of primordial germ cells on the developing gonads of an embryo. One type of gonadal dysgenesis is the development of functionless, fibrous tissue, termed streak gonads, instead of reproductive tissue. Streak gonads are a form of aplasia, resulting in hormonal failure that manifests as sexual infantism and infertility, with no initiation of puberty and secondary sex characteristics.

<span class="mw-page-title-main">Partial androgen insensitivity syndrome</span> Medical condition

Partial androgen insensitivity syndrome (PAIS) is a condition that results in the partial inability of the cell to respond to androgens. It is an X linked recessive condition. The partial unresponsiveness of the cell to the presence of androgenic hormones impairs the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does not significantly impair female genital or sexual development. As such, the insensitivity to androgens is clinically significant only when it occurs in individuals with a Y chromosome. Clinical features include ambiguous genitalia at birth and primary amenhorrhoea with clitoromegaly with inguinal masses. Müllerian structures are not present in the individual.

<span class="mw-page-title-main">Estrogen insensitivity syndrome</span> Medical condition

Estrogen insensitivity syndrome (EIS), or estrogen resistance, is a form of congenital estrogen deficiency or hypoestrogenism which is caused by a defective estrogen receptor (ER) – specifically, the estrogen receptor alpha (ERα) – that results in an inability of estrogen to mediate its biological effects in the body. Congenital estrogen deficiency can alternatively be caused by a defect in aromatase, the enzyme responsible for the biosynthesis of estrogens, a condition which is referred to as aromatase deficiency and is similar in symptomatology to EIS.

<span class="mw-page-title-main">SRD5A2</span> Protein-coding gene in the species Homo sapiens

The human gene SRD5A2 encodes the 3-oxo-5α-steroid 4-dehydrogenase 2 enzyme, also known as 5α-reductase type 2 (5αR2), one of three isozymes of 5α-reductase.

<span class="mw-page-title-main">Aromatase deficiency</span> Medical condition

Aromatase deficiency is a rare condition characterized by extremely low levels or complete absence of the enzyme aromatase activity in the body. It is an autosomal recessive disease resulting from various mutations of gene CYP19 (P450arom) which can lead to ambiguous genitalia and delayed puberty in females, continued linear growth into adulthood and osteoporosis in males and virilization in pregnant mothers. As of 2020, fewer than 15 cases have been identified in genetically male individuals and at least 30 cases in genetically female individuals.

Breast development, also known as mammogenesis, is a complex biological process in primates that takes place throughout a female's life.

<span class="mw-page-title-main">Mild androgen insensitivity syndrome</span> Medical condition

Mild androgen insensitivity syndrome (MAIS) is an intersex variation that results in a mild impairment of the cell's ability to respond to androgens. The degree of impairment is sufficient to impair spermatogenesis and / or the development of secondary sexual characteristics at puberty in males, but does not affect genital differentiation or development. Female genital and sexual development is not significantly affected by the insensitivity to androgens; as such, MAIS is only diagnosed in males. The clinical phenotype associated with MAIS is a normal male habitus with mild spermatogenic defect and / or reduced secondary terminal hair.

Hypergonadotropic hypogonadism (HH), also known as primary or peripheral/gonadal hypogonadism or primary gonadal failure, is a condition which is characterized by hypogonadism which is due to an impaired response of the gonads to the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in turn a lack of sex steroid production. As compensation and the lack of negative feedback, gonadotropin levels are elevated. Individuals with HH have an intact and functioning hypothalamus and pituitary glands so they are still able to produce FSH and LH. HH may present as either congenital or acquired, but the majority of cases are of the former nature. HH can be treated with hormone replacement therapy.

<span class="mw-page-title-main">Leydig cell hypoplasia</span> Medical condition

Leydig cell hypoplasia (LCH), also known as Leydig cell agenesis, is a rare autosomal recessive genetic and endocrine syndrome affecting an estimated 1 in 1,000,000 individuals with XY chromosomes. It is characterized by an inability of the body to respond to luteinizing hormone (LH), a gonadotropin which is normally responsible for signaling Leydig cells of the testicles to produce testosterone and other androgen sex hormones. The condition manifests itself as pseudohermaphroditism, hypergonadotropic hypogonadism, reduced or absent puberty, and infertility.

Hormonal breast enhancement or augmentation is a highly experimental potential medical treatment for the breasts in which hormones or hormonal agents such as estrogen, progesterone, growth hormone (GH), and insulin-like growth factor 1 (IGF-1) are utilized or manipulated to produce breast enlargement in women. It is a possible alternative or supplement to surgical breast augmentation with breast implants or fat transfer and other means of medical breast enlargement.

Hypergonadotropic hypergonadism is an endocrine situation and subtype of hypergonadism in which both gonadotropin levels and gonadal function, such as sex hormone production, are abnormally high. It can be associated with hyperandrogenism and hyperestrogenism and with gonadal cysts and tumors. It can be caused by medications such as gonadotropins, gonadotropin-releasing hormone agonists, nonsteroidal antiandrogens, and selective estrogen receptor modulators, as well as conditions like human chorionic gonadotropin-secreting tumors, complete androgen insensitivity syndrome, and estrogen insensitivity syndrome.

The pharmacology of estradiol, an estrogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.

<span class="mw-page-title-main">Estrogen provocation test</span> Medical diagnostic method

The estrogen provocation test, also known as the estrogen stimulation test or estrogen challenge test, is a diagnostic procedure used to evaluate the function of the hypothalamic–pituitary–gonadal axis. It involves the administration of a large amount of estrogen, resulting in estrogenic exposure similar to or greater than normal preovulatory estradiol levels, in an attempt to induce a positive feedback surge in levels of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Estrogens that have been used in the estrogen provocation test include estradiol benzoate, estradiol valerate, ethinylestradiol, and high-dose transdermal estradiol patches. The test involves sustained estrogenic exposure equivalent to estradiol levels of 200 to 300 pg/mL or more for at least 50 hours and results in a surge in gonadotropin levels about 32 to 72 hours following initiation of estrogenic exposure. Levels of LH and FSH increase during the gonadotropin surge by about 10-fold and 4-fold, respectively.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Hughes IA, Deeb A (December 2006). "Androgen resistance". Best Pract. Res. Clin. Endocrinol. Metab. 20 (4): 577–98. doi:10.1016/j.beem.2006.11.003. PMID   17161333.
  2. 1 2 3 4 5 6 7 Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A (2008). "Androgen insensitivity syndrome: clinical features and molecular defects". Hormones (Athens). 7 (3): 217–29. doi: 10.14310/horm.2002.1201 . PMID   18694860.
  3. 1 2 Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (June 1995). "Androgen receptor defects: historical, clinical, and molecular perspectives". Endocr. Rev. 16 (3): 271–321. doi:10.1210/edrv-16-3-271. PMID   7671849.
  4. 1 2 Giwercman YL, Nordenskjöld A, Ritzén EM, Nilsson KO, Ivarsson SA, Grandell U, Wedell A (June 2002). "An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity". J. Clin. Endocrinol. Metab. 87 (6): 2623–8. doi: 10.1210/jcem.87.6.8518 . PMID   12050225.
  5. 1 2 3 Zuccarello D, Ferlin A, Vinanzi C, Prana E, Garolla A, Callewaert L, Claessens F, Brinkmann AO, Foresta C (April 2008). "Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility". Clin. Endocrinol. 68 (4): 580–8. doi:10.1111/j.1365-2265.2007.03069.x. PMID   17970778. S2CID   2783902.
  6. 1 2 Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D, Cazzadore C, Foresta C (November 2006). "Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations". Clin. Endocrinol. 65 (5): 606–10. doi:10.1111/j.1365-2265.2006.02635.x. PMID   17054461. S2CID   33713391.
  7. 1 2 3 Stouffs K, Tournaye H, Liebaers I, Lissens W (2009). "Male infertility and the involvement of the X chromosome". Hum. Reprod. Update. 15 (6): 623–37. doi: 10.1093/humupd/dmp023 . PMID   19515807.
  8. ↑ Giwercman YL, Nikoshkov A, Byström B, Pousette A, Arver S, Wedell A (June 2001). "A novel mutation (N233K) in the transactivating domain and the N756S mutation in the ligand binding domain of the androgen receptor gene are associated with male infertility". Clin. Endocrinol. 54 (6): 827–34. doi:10.1046/j.1365-2265.2001.01308.x. PMID   11422119. S2CID   23554058.
  9. ↑ Lund A, Juvonen V, Lähdetie J, Aittomäki K, Tapanainen JS, Savontaus ML (June 2003). "A novel sequence variation in the transactivation regulating domain of the androgen receptor in two infertile Finnish men". Fertil. Steril. 79 (Suppl 3): 1647–8. doi: 10.1016/s0015-0282(03)00256-5 . PMID   12801573.
  10. ↑ Forman D, Pike M, Davey G, Dawson S, Baker K, Chilvers C, Oliver R, Coupland C (1994). "Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise". British Medical Journal. 308 (6941): 1393–1398. doi:10.1136/bmj.308.6941.1393. PMC   2540340 . PMID   7912596.
  11. ↑ Ozülker T, Ozpaçaci T, Ozülker F, Ozekici U, Bilgiç R, Mert M (January 2010). "Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome". Ann Nucl Med. 24 (1): 35–9. doi:10.1007/s12149-009-0321-x. PMID   19957213. S2CID   10450803.
  12. ↑ Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK (November 2007). "Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis". J. Clin. Endocrinol. Metab. 92 (11): 4319–26. doi: 10.1210/jc.2007-1110 . PMID   17684052.
  13. ↑ Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R (November 2005). "Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients". J. Clin. Endocrinol. Metab. 90 (11): 6162–9. doi: 10.1210/jc.2005-0179 . PMID   16118342.
  14. ↑ Gottlieb B, Lombroso R, Beitel LK, Trifiro MA (January 2005). "Molecular pathology of the androgen receptor in male (in)fertility". Reprod. Biomed. Online. 10 (1): 42–8. doi:10.1016/S1472-6483(10)60802-4. PMID   15705293.
  15. ↑ Ahmed SF, Cheng A, Hughes IA (April 1999). "Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome". Arch. Dis. Child. 80 (4): 324–9. doi:10.1136/adc.80.4.324. PMC   1717906 . PMID   10086936.
  16. ↑ Jirásek JE, Simpson JL (1976). Disorders of sexual differentiation: etiology and clinical delineation. Boston: Academic Press. ISBN   978-0-12-644450-6.
  17. ↑ Gilbert SF (2000). Developmental biology . Sunderland, Mass: Sinauer Associates. ISBN   978-0-87893-243-6.
  18. 1 2 3 4 5 6 7 8 Oakes MB, Eyvazzadeh AD, Quint E, Smith YR (December 2008). "Complete androgen insensitivity syndrome--a review". J Pediatr Adolesc Gynecol. 21 (6): 305–10. doi:10.1016/j.jpag.2007.09.006. PMID   19064222.
  19. 1 2 3 4 5 6 Nichols JL, Bieber EJ, Gell JS (2009). "Case of sisters with complete androgen insensitivity syndrome and discordant Müllerian remnants". Fertil. Steril. 91 (3): 932.e15–8. doi: 10.1016/j.fertnstert.2008.09.027 . PMID   18930210.
  20. 1 2 Melo KF, Mendonca BB, Billerbeck AE, Costa EM, Inácio M, Silva FA, Leal AM, Latronico AC, Arnhold IJ (July 2003). "Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene". J. Clin. Endocrinol. Metab. 88 (7): 3241–50. doi: 10.1210/jc.2002-021658 . PMID   12843171.
  21. 1 2 3 Minto CL, Liao KL, Conway GS, Creighton SM (July 2003). "Sexual function in women with complete androgen insensitivity syndrome". Fertil. Steril. 80 (1): 157–64. CiteSeerX   10.1.1.543.7011 . doi:10.1016/S0015-0282(03)00501-6. PMID   12849818.
  22. ↑ Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K (January 1997). "Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group". Eur. J. Pediatr. 156 (1): 7–14. doi:10.1007/s004310050542. PMID   9007482. S2CID   34427651.
  23. 1 2 3 4 5 6 7 Ismail-Pratt IS, Bikoo M, Liao LM, Conway GS, Creighton SM (July 2007). "Normalization of the vagina by dilator treatment alone in Complete Androgen Insensitivity Syndrome and Mayer-Rokitansky-Kuster-Hauser Syndrome". Hum. Reprod. 22 (7): 2020–4. doi:10.1093/humrep/dem074. PMID   17449508.
  24. ↑ Weber AM, Walters MD, Schover LR, Mitchinson A (December 1995). "Vaginal anatomy and sexual function". Obstet Gynecol. 86 (6): 946–9. doi:10.1016/0029-7844(95)00291-X. PMID   7501345. S2CID   6528527.
  25. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Quint EH, McCarthy JD, Smith YR (March 2010). "Vaginal surgery for congenital anomalies". Clin Obstet Gynecol. 53 (1): 115–24. doi:10.1097/GRF.0b013e3181cd4128. PMID   20142648. S2CID   41259739.
  26. ↑ Achermann JC, Jameson JL (2006). "Disorders of sexual differentiation". In Hauser SL, Kasper DL, Fauci AS, Braunwald E, Longo DL (eds.). Harrison's endocrinology. New York: McGraw-Hill Medical Pub. Division. pp. 161–172. ISBN   978-0-07-145744-6.
  27. ↑ Simpson JL, Rebar RW (2002). Hung, Wellington, Becker, Kenneth L., Bilezikian, John P., William J Bremner (eds.). Principles and Practice of Endocrinology and Metabolism. Hagerstwon, MD: Lippincott Williams & Wilkins. pp. 852–885. ISBN   978-0-7817-4245-0.
  28. ↑ Decaestecker K, Philibert P, De Baere E, Hoebeke P, Kaufman JM, Sultan C, T'Sjoen G (May 2008). "A novel mutation c.118delA in exon 1 of the androgen receptor gene resulting in complete androgen insensitivity syndrome within a large family". Fertil. Steril. 89 (5): 1260.e3–7. doi: 10.1016/j.fertnstert.2007.04.057 . PMID   17714709.
  29. ↑ Morris JM (June 1953). "The syndrome of testicular feminization in male pseudohermaphrodites". Am. J. Obstet. Gynecol. 65 (6): 1192–1211. doi:10.1016/0002-9378(53)90359-7. PMID   13057950.
  30. ↑ Müller J (October 1984). "Morphometry and histology of gonads from twelve children and adolescents with the androgen insensitivity (testicular feminization) syndrome". J. Clin. Endocrinol. Metab. 59 (4): 785–9. doi:10.1210/jcem-59-4-785. PMID   6480805.
  31. ↑ Boehmer AL, Brinkmann O, Brüggenwirth H, van Assendelft C, Otten BJ, Verleun-Mooijman MC, Niermeijer MF, Brunner HG, Rouwé CW, Waelkens JJ, Oostdijk W, Kleijer WJ, van der Kwast TH, de Vroede MA, Drop SL (September 2001). "Genotype versus phenotype in families with androgen insensitivity syndrome". J. Clin. Endocrinol. Metab. 86 (9): 4151–60. doi: 10.1210/jcem.86.9.7825 . PMID   11549642.
  32. ↑ Johnston DS, Russell LD, Friel PJ, Griswold MD (June 2001). "Murine germ cells do not require functional androgen receptors to complete spermatogenesis following spermatogonial stem cell transplantation". Endocrinology. 142 (6): 2405–8. doi: 10.1210/endo.142.6.8317 . hdl: 1773/4480 . PMID   11356688.
  33. ↑ Yong EL, Loy CJ, Sim KS (2003). "Androgen receptor gene and male infertility". Hum. Reprod. Update. 9 (1): 1–7. doi: 10.1093/humupd/dmg003 . PMID   12638777.
  34. 1 2 3 4 Hughes IA, Houk C, Ahmed SF, Lee PA (July 2006). "Consensus statement on management of intersex disorders". Arch. Dis. Child. 91 (7): 554–63. doi:10.1136/adc.2006.098319. PMC   2082839 . PMID   16624884.
  35. ↑ Hannema SE, Scott IS, Hodapp J, Martin H, Coleman N, Schwabe JW, Hughes IA (November 2004). "Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome". J. Clin. Endocrinol. Metab. 89 (11): 5815–22. doi: 10.1210/jc.2004-0709 . PMID   15531547.
  36. ↑ Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B (1999). Regulation of androgen action. Vitamins & Hormones. Vol. 55. pp. 309–52. doi:10.1016/S0083-6729(08)60938-3. ISBN   9780127098555. PMID   9949684.{{cite book}}: |journal= ignored (help)
  37. ↑ Kokontis JM, Liao S (1999). Molecular action of androgen in the normal and neoplastic prostate. Vitamins & Hormones. Vol. 55. pp. 219–307. doi:10.1016/s0083-6729(08)60937-1. ISBN   9780127098555. PMID   9949683.{{cite book}}: |journal= ignored (help)
  38. 1 2 Rajender S, Gupta NJ, Chakrabarty B, Singh L, Thangaraj K (March 2009). "Ala 586 Asp mutation in androgen receptor disrupts transactivation function without affecting androgen binding". Fertil. Steril. 91 (3): 933.e23–8. doi: 10.1016/j.fertnstert.2008.10.041 . PMID   19062009.
  39. ↑ Chen CP, Chen SR, Wang TY, Wang W, Hwu YM (July 1999). "A frame shift mutation in the DNA-binding domain of the androgen receptor gene associated with complete androgen insensitivity, persistent müllerian structures, and germ cell tumors in dysgenetic gonads". Fertil. Steril. 72 (1): 170–3. doi: 10.1016/S0015-0282(99)00169-7 . PMID   10428170.
  40. ↑ Papadimitriou DT, Linglart A, Morel Y, Chaussain JL (2006). "Puberty in subjects with complete androgen insensitivity syndrome". Horm. Res. 65 (3): 126–31. doi:10.1159/000091592 (inactive 1 November 2024). PMID   16491011. S2CID   20105726.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  41. 1 2 3 Wisniewski AB, Migeon CJ, Meyer-Bahlburg HFL, Gearhart JP, Berkovitz GD, Brown TR, Money J (2000). "Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome". J Clin Endocrinol Metab. 85 (8): 2664–2669. doi: 10.1210/jcem.85.8.6742 . PMID   10946863.
  42. ↑ Varrela J, Alvesalo L, Vinkka H (1984). "Body size and shape in 46,XY females with complete testicular feminization". Annals of Human Biology. 11 (4): 291–301. doi:10.1080/03014468400007191. PMID   6465836.
  43. ↑ Alvesalo L, Varrela J (September 1980). "Permanent tooth sizes in 46,XY females". American Journal of Human Genetics. 32 (5): 736–42. PMC   1686090 . PMID   7424913.
  44. ↑ Pietilä K, Grön M, Alvesalo L (August 1997). "The craniofacial complex in karyotype 46,XY females". Eur J Orthod. 19 (4): 383–9. doi: 10.1093/ejo/19.4.383 . PMID   9308259.
  45. ↑ Sultan C, Lumbroso S, Paris F, Jeandel C, Terouanne B, Belon C, Audran F, Poujol N, Georget V, Gobinet J, Jalaguier S, Auzou G, Nicolas JC (August 2002). "Disorders of androgen action". Semin. Reprod. Med. 20 (3): 217–28. doi:10.1055/s-2002-35386. PMID   12428202. S2CID   41205149.
  46. ↑ Zachmann M, Prader A, Sobel EH, Crigler JF, Ritzén EM, Atarés M, Ferrandez A (May 1986). "Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls". J. Pediatr. 108 (5 Pt 1): 694–7. doi:10.1016/S0022-3476(86)81043-5. PMID   3701515.
  47. ↑ Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA (August 2003). "Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?". Cornea. 22 (6): 516–21. doi:10.1097/00003226-200308000-00006. PMID   12883343. S2CID   29374194.
  48. ↑ Imperato-Mcginley, J.; Gautier, T.; Cai, L. Q.; Yee, B.; Epstein, J.; Pochi, P. (1993). "The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity". The Journal of Clinical Endocrinology & Metabolism. 76 (2): 524–528. doi:10.1210/jcem.76.2.8381804. PMID   8381804 . Retrieved 2023-08-30.
  49. 1 2 3 Bertelloni S, Dati E, Baroncelli GI, Hiort O (2011). "Hormonal management of complete androgen insensitivity syndrome from adolescence onward". Horm Res Paediatr. 76 (6): 428–33. doi:10.1159/000334162. PMID   22156544. S2CID   35239423.
  50. 1 2 3 King TF, Wat WZ, Creighton SM, Conway GS (August 2017). "Bone mineral density in complete androgen insensitivity syndrome and the timing of gonadectomy". Clin. Endocrinol. (Oxf). 87 (2): 136–140. doi:10.1111/cen.13368. PMID   28493277. S2CID   4877830.
  51. ↑ Heyns W (1977). "The steroid-binding beta-globulin of human plasma". Adv Steroid Biochem Pharmacol. 6: 59–79. PMID   339697.
  52. ↑ Antonio R. Gargiulo (23 December 2017). Yen & Jaffe's Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 250–. ISBN   978-0-323-58232-2.
  53. ↑ Schindler AE, Freidrich E, Keller E, Joel EW, Jaeger-Whitegiver ER (November 1975). "In vivo und in vitro Untersuchungen bei Patienten mit testikulärer Feminisierung" [In-vivo and in-vitro studies of patients with testicular feminization]. Arch Gynakol (in German). 219 (1–4): 584. doi:10.1007/BF00669260. PMID   1243499. S2CID   41243904.
  54. ↑ Blumenthal NJ, Lubbe F, Harnekar AB, Adno A (November 1982). "Complete androgen insensitivity". S. Afr. Med. J. 62 (22): 812–4. PMID   7147110.
  55. ↑ Adam H. Balen; Sarah M. Creighton; Melanie C. Davies; Richard Stanhope; Jane MacDougall (April 2004). Paediatric and Adolescent Gynaecology: A Multidisciplinary Approach. Cambridge University Press. pp. 282–. ISBN   978-0-521-80961-0.
  56. ↑ Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS (December 1995). "Osteopenia as a feature of the androgen insensitivity syndrome". Clin. Endocrinol. (Oxf). 43 (6): 671–5. doi:10.1111/j.1365-2265.1995.tb00533.x. PMID   8736267. S2CID   23119343.
  57. ↑ Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, Zhang H, Wang JC, Tao S, Liu X, Luo Z (January 2002). "Male fertility is compatible with an Arg(840)Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome". J. Clin. Endocrinol. Metab. 87 (1): 347–51. doi: 10.1210/jcem.87.1.8167 . PMID   11788673.
  58. ↑ Menakaya UA, Aligbe J, Iribhogbe P, Agoreyo F, Okonofua FE (May 2005). "Complete androgen insensitivity syndrome with persistent Mullerian derivatives: a case report". J Obstet Gynaecol. 25 (4): 403–5. doi:10.1080/01443610500143226. PMID   16091340. S2CID   25377683.
  59. ↑ Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, Wedell A, Skakkebaek NE (June 2000). "Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene". J. Clin. Endocrinol. Metab. 85 (6): 2253–9. doi: 10.1210/jcem.85.6.6626 . PMID   10852459.
  60. 1 2 Danilovic DL, Correa PH, Costa EM, Melo KF, Mendonca BB, Arnhold IJ (March 2007). "Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene". Osteoporos Int. 18 (3): 369–74. doi:10.1007/s00198-006-0243-6. PMID   17077943. S2CID   21378953.
  61. 1 2 3 Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J (August 2006). "Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes". J. Clin. Endocrinol. Metab. 91 (8): 3017–23. doi: 10.1210/jc.2005-2809 . PMID   16735493.
  62. 1 2 3 4 5 Marcus R, Leary D, Schneider DL, Shane E, Favus M, Quigley CA (March 2000). "The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome". J. Clin. Endocrinol. Metab. 85 (3): 1032–7. doi: 10.1210/jcem.85.3.6428 . PMID   10720035.
  63. 1 2 Bertelloni S, Baroncelli GI, Federico G, Cappa M, Lala R, Saggese G (1998). "Altered bone mineral density in patients with complete androgen insensitivity syndrome". Horm. Res. 50 (6): 309–14. doi:10.1159/000023296 (inactive 1 November 2024). PMID   9973670. S2CID   22470669.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  64. 1 2 3 Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS (December 1995). "Osteopenia as a feature of the androgen insensitivity syndrome". Clin. Endocrinol. 43 (6): 671–5. doi:10.1111/j.1365-2265.1995.tb00533.x. PMID   8736267. S2CID   23119343.
  65. ↑ Muñoz-Torres M, Jódar E, Quesada M, Escobar-Jiménez F (August 1995). "Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy". Calcif. Tissue Int. 57 (2): 94–6. doi:10.1007/BF00298426. PMID   7584881. S2CID   30714697.
  66. 1 2 3 Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebaek NE, Coleman N, Hughes IA (March 2006). "Testicular development in the complete androgen insensitivity syndrome". J. Pathol. 208 (4): 518–27. doi: 10.1002/path.1890 . PMID   16400621. S2CID   20730666.
  67. ↑ Rutgers JL, Scully RE (1991). "The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases". Int. J. Gynecol. Pathol. 10 (2): 126–44. doi:10.1097/00004347-199104000-00002. PMID   2032766. S2CID   45886011.
  68. 1 2 3 Manuel M, Katayama PK, Jones HW (February 1976). "The age of occurrence of gonadal tumors in intersex patients with a Y chromosome". Am. J. Obstet. Gynecol. 124 (3): 293–300. doi:10.1016/0002-9378(76)90160-5. PMID   1247071.
  69. ↑ Slijper FM, Drop SL, Molenaar JC, de Muinck Keizer-Schrama SM (April 1998). "Long-term psychological evaluation of intersex children". Arch Sex Behav. 27 (2): 125–44. doi:10.1023/A:1018670129611. PMID   9562897. S2CID   8255476.
  70. 1 2 Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J (October 2012). "Androgen insensitivity syndrome" (PDF). Lancet. 380 (9851): 1419–28. doi:10.1016/S0140-6736(12)60071-3. PMID   22698698. S2CID   1602036.
  71. ↑ Tiefenbacher K, Daxenbichler G (2008). "The Role of Androgens in Normal and Malignant Breast Tissue". Breast Care (Basel). 3 (5): 325–331. doi:10.1159/000158055. PMC   2931104 . PMID   20824027.
  72. 1 2 Charles G. D. Brook; Peter Clayton; Rosalind Brown (22 September 2011). Brook's Clinical Pediatric Endocrinology. John Wiley & Sons. pp. 200–. ISBN   978-1-4443-1673-5.
  73. 1 2 Adam H. Balen; Sarah M. Creighton; Melanie C. Davies; Jane MacDougall; Richard Stanhope (1 April 2004). Paediatric and Adolescent Gynaecology: A Multidisciplinary Approach. Cambridge University Press. pp. 284, 287. ISBN   978-1-107-32018-5.
  74. ↑ Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (12 May 2011). Williams Textbook of Endocrinology E-Book. Elsevier Health Sciences. pp. 909–. ISBN   978-1-4377-3600-7.
  75. ↑ Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA (August 2015). "Androgen insensitivity syndrome". Best Pract. Res. Clin. Endocrinol. Metab. 29 (4): 569–80. doi:10.1016/j.beem.2015.04.005. PMID   26303084.
  76. ↑ Davis SE, Wallace AM (2001). "A 19 year old with complete androgen insensitivity syndrome and juvenile fibroadenoma of the breast". Breast J. 7 (6): 430–3. doi: 10.1046/j.1524-4741.2001.07610.x . PMID   11843857. S2CID   22116213.
  77. ↑ Charles G. D. Brook; Mehul T. Dattani (16 February 2012). Handbook of Clinical Pediatric Endocrinology. John Wiley & Sons. pp. 54–. ISBN   978-1-119-96813-9.
  78. ↑ Hoefgen HR, Merritt DF (August 2015). "Invasive Ductal Carcinoma in a 46,XY Partial Androgen Insensitivity Syndrome Patient on Hormone Therapy". J Pediatr Adolesc Gynecol. 28 (4): e95–7. doi:10.1016/j.jpag.2014.08.005. PMID   26024935.
  79. ↑ Borisa AD, Puri Y, Wakade V, Alagappan C, Agarkhedkar N (2006). "Complete Androgen Insensitivity Syndrome Presenting as Bilateral Inguinal Hernia". Bombay Hosp J. 48: 668–673.
  80. ↑ Michailidis GD, Papageorgiou P, Morris RW, Economides DL (July 2003). "The use of three-dimensional ultrasound for fetal gender determination in the first trimester". Br J Radiol. 76 (907): 448–51. doi:10.1259/bjr/13479830. PMID   12857703.
  81. ↑ Jones, Tiffany (2017). "Intersex and Families: Supporting Family Members With Intersex Variations". Journal of Family Strengths. 17 (2). doi: 10.58464/2168-670X.1345 .
  82. 1 2 Kulshreshtha B, Philibert P, Eunice M, Khandelwal SK, Mehta M, Audran F, Paris F, Sultan C, Ammini AC (December 2009). "Apparent male gender identity in a patient with complete androgen insensitivity syndrome". Arch Sex Behav. 38 (6): 873–5. doi:10.1007/s10508-009-9526-2. PMID   19636694. S2CID   207089643.
  83. ↑ Brunner, Franziska; Fliegner, Maike; Krupp, Kerstin; Rall, Katharina; Brucker, Sara; Richter-Appelt, Hertha (2016). "Gender Role, Gender Identity and Sexual Orientation in CAIS ("XY-Women") Compared With Subfertile and Infertile 46,XX Women". Journal of Sex Research. 53 (1): 109–124. doi:10.1080/00224499.2014.1002124. ISSN   1559-8519. PMID   26133743.
  84. ↑ Tsjoen G, De Cuypere G, Monstrey S, Hoebeke P, Freedman FK, Appari M, Holterhus PM, Van Borsel J, Cools M (April 2010). "Male gender identity in complete androgen insensitivity syndrome". Arch. Sex. Behav. 40 (3): 635–638. doi:10.1007/s10508-010-9624-1. PMID   20358272. S2CID   19291058.
  85. ↑ Grover S (1996). "Stretch Yourself". Alias. 1: 76.
  86. 1 2 Submission 88 to the Australian Senate inquiry on the involuntary or coerced sterilisation of people with disabilities in Australia, Australasian Paediatric Endocrine Group (APEG), 27 June 2013
  87. ↑ Hurt WG, Bodurtha JN, McCall JB, Ali MM (September 1989). "Seminoma in pubertal patient with androgen insensitivity syndrome". Am. J. Obstet. Gynecol. 161 (3): 530–1. doi:10.1016/0002-9378(89)90350-5. PMID   2782332.
  88. ↑ "Intersex Genital Mutilation, Intersex Youth and Human Rights" (PDF).
  89. ↑ Carpenter M (December 2018). "Intersex Variations, Human Rights, and the International Classification of Diseases". Health and Human Rights. 20 (2): 205–214. PMC   6293350 . PMID   30568414.
  90. ↑ Greenberg JA (June 2017). "Legal, ethical, and human rights considerations for physicians treating children with atypical or ambiguous genitalia". Seminars in Perinatology. 41 (4): 252–255. doi:10.1053/j.semperi.2017.03.012. PMID   28478089.
  91. ↑ Ko, J. K.; King, T. F.; Williams, L.; Creighton, S. M.; Conway, G. S. (2017). "Hormone replacement treatment choices in complete androgen insensitivity syndrome: an audit of an adult clinic - PMC". Endocrine Connections. 6 (6): 375–379. doi:10.1530/EC-17-0083. PMC   5527352 . PMID   28615185.
  92. ↑ Weidler, Erica M.; Linnaus, Maria E.; Baratz, Arlene B.; Goncalves, Luis F.; Bailey, Smita; Hernandez, S. Janett; Gomez-Lobo, Veronica; van Leeuwen, Kathleen (December 2019). "A Management Protocol for Gonad Preservation in Patients with Androgen Insensitivity Syndrome". Journal of Pediatric and Adolescent Gynecology. 32 (6): 605–611. doi:10.1016/j.jpag.2019.06.005. ISSN   1873-4332. PMC   6917890 . PMID   31233832.
  93. ↑ Motoyama S, Laoag-Fernandez JB, Mochizuki S, Yamabe S, Maruo T (May 2003). "Vaginoplasty with Interceed absorbable adhesion barrier for complete squamous epithelialization in vaginal agenesis". Am. J. Obstet. Gynecol. 188 (5): 1260–4. doi:10.1067/mob.2003.317. PMID   12748495.
  94. ↑ Jackson ND, Rosenblatt PL (December 1994). "Use of Interceed Absorbable Adhesion Barrier for vaginoplasty". Obstet Gynecol. 84 (6): 1048–50. PMID   7970464.
  95. 1 2 Steiner E, Woernle F, Kuhn W, Beckmann K, Schmidt M, Pilch H, Knapstein PG (January 2002). "Carcinoma of the neovagina: case report and review of the literature". Gynecol. Oncol. 84 (1): 171–5. doi:10.1006/gyno.2001.6417. PMID   11748997.
  96. 1 2 3 4 5 Breech LL (2008). "Complications of vaginoplasty and clitoroplasty". In Teich S, Caniano DA (eds.). Reoperative pediatric surgery. Totowa, N.J: Humana. pp. 499–514. ISBN   978-1-58829-761-7.
  97. ↑ Barutçu, Ali; Akgüner, Muharrem (November 1998). "McIndoe Vaginoplasty with the Inflatable Vaginal Stent". Annals of Plastic Surgery. 41 (5): 568–9. doi:10.1097/00000637-199811000-00020. PMID   9827964.
  98. ↑ Coskun, Ayhan; Coban, Yusuf Kenan; Vardar, Mehmet Ali; Dalay, Ahmet Cemil (10 July 2007). "The use of a silicone-coated acrylic vaginal stent in McIndoe vaginoplasty and review of the literature concerning silicone-based vaginal stents: a case report". BMC Surgery. 7 (1): 13. doi: 10.1186/1471-2482-7-13 . PMC   1947946 . PMID   17623058.
  99. ↑ Antoniadis, N; Charles, G; Mejías, I; Pabón, R (March 2011). "Vaginoplastia: modificación de la técnica de McIndoe usando esponja de gel hemostático" [Vaginoplasty: modification to McIndoe techique[sic] using hemostatic gel sponge]. Cirugía Plástica Ibero-Latinoamericana. 37 (1): 73–77. doi: 10.4321/S0376-78922011000100010 . S2CID   73403359.
  100. ↑ Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (11 November 2015). Williams Textbook of Endocrinology E-Book. Elsevier Health Sciences. pp. 933–. ISBN   978-0-323-34157-8.
  101. ↑ M. Sperling (1 January 2008). Pediatric Endocrinology. Elsevier Health Sciences. pp. 670–. ISBN   978-1-4160-4090-3.
  102. 1 2 Mendoza N, Motos MA (January 2013). "Androgen insensitivity syndrome". Gynecol. Endocrinol. 29 (1): 1–5. doi:10.3109/09513590.2012.705378. PMID   22812659. S2CID   37882159.
  103. 1 2 Mendoza, Nicolas; Rodriguez-Alcalá, Cristina; Motos, Miguel Angel; Salamanca, Alberto (2017). "Androgen Insensitivity Syndrome: An Update on the Management of Adolescents and Young People". Journal of Pediatric and Adolescent Gynecology. 30 (1): 2–8. doi:10.1016/j.jpag.2016.08.013. ISSN   1083-3188.
  104. ↑ Imperato-McGinley J, Canovatchel WJ (April 1992). "Complete androgen insensitivity Pathophysiology, diagnosis, and management". Trends Endocrinol. Metab. 3 (3): 75–81. doi:10.1016/1043-2760(92)90016-T. PMID   18407082. S2CID   35500255.
  105. 1 2 Patterson, Mark N.; McPhaul, Michael J.; Hughes, Ieuan A. (1994). "8 Androgen insensitivity syndrome". Baillière's Clinical Endocrinology and Metabolism. 8 (2): 379–404. doi:10.1016/S0950-351X(05)80258-7. ISSN   0950-351X. PMID   8092978.[ permanent dead link ]
  106. ↑ "Georgiann Davis". The Interface Project . November 7, 2012.
  107. ↑ Morrison, Sarah (30 November 2013). "Special report: Intersex women speak out to protect the next generation". The Independent . Retrieved 19 November 2015.
Information
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.